Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 15Terminated 4Recruiting 4Active not recruiting 4Withdrawn 2

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 11Waldenstrom Macroglobulinemia 4Recurrence 4Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma 4Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 3Lymphoma, B-Cell 3Leukemia 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Acute 2Burkitt Lymphoma 2Squamous Cell Carcinoma of Head and Neck 1Smoldering Multiple Myeloma 1Neoplasms, Plasma Cell 1Multi-centric Castleman's Disease 1Mastocytosis, Systemic 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large-Cell, Immunoblastic 1Leukemia, Mast-Cell 1Leukemia, Lymphoid 1Leukemia, Hairy Cell 1Intraocular Lymphoma 1Hypergammaglobulinemia 1Hematologic Neoplasms 1Hematologic Diseases 1

Interventions

Rituximab 66Cyclophosphamide 52fludarabine phosphate 26fludarabine 22Filgrastim 21Vincristine 19Methotrexate 19Melphalan 19Doxorubicin 18Radiotherapy 17Etoposide 17Prednisone 16Tacrolimus 15Whole-Body Irradiation 14Mycophenolic Acid 14Cytarabine 14Peripheral Blood Stem Cell Transplantation 13Gemcitabine 13Cyclosporine 13Antilymphocyte Serum 13Lenalidomide 12Busulfan 11Bortezomib 11Granulocyte Colony-Stimulating Factor 9Alemtuzumab 9sargramostim 8Dexamethasone 8Cord Blood Stem Cell Transplantation 8pembrolizumab 7ibritumomab tiuxetan 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Lymphoma × ibrutinib × Clear all
NCT03876028 2023-01-31

Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients

Novartis

Phase 1 Terminated
10 enrolled
Lymphoid

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02356458 2022-03-11

Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma

Swiss Cancer Institute

Phase 1/2 Terminated
58 enrolled
Lymphoid

Lymphoma, Neoplasms, Recurrence, Lymphoma, Mantle-Cell

NCT02269085 2019-02-28

Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma

M.D. Anderson Cancer Center

Phase 1 Terminated
8 enrolled
Lymphoid

Lymphoma, Recurrence, Lymphoma, Mantle-Cell

NCT02272686 2018-12-05

Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma

M.D. Anderson Cancer Center

Phase 2 Terminated
1 enrolled 5 charts
Lymphoid

Lymphoma, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡